2014
Primary Androgen Deprivation Therapy for Prostate Cancer in Koreans: A Retrospective Multicenter Study
Seo W, Kang P, Kim T, Moon K, Chung J, Lee D, Kim I, Min K, Chung J, Kim W, Kang D. Primary Androgen Deprivation Therapy for Prostate Cancer in Koreans: A Retrospective Multicenter Study. The World Journal Of Men's Health 2014, 32: 159-166. PMID: 25606565, PMCID: PMC4298819, DOI: 10.5534/wjmh.2014.32.3.159.Peer-Reviewed Original ResearchPrimary androgen deprivation therapyAndrogen deprivation therapyAdvanced prostate cancerProstate cancerDeprivation therapyDefinitive therapyMetastatic stageMedian pretreatment PSA levelBetter progression-free survivalProstate-specific antigen progressionPSA progression ratePretreatment PSA levelCharacteristics of patientsProgression-free survivalRetrospective multicenter studyMedian survival timeHigher clinical stageAndrogen blockadeMedical comorbiditiesPSA progressionPSA changePSA levelsClinical factorsMedian ageClinical efficacy
2011
Endocrine therapy for prostate cancer: review of the latest clinical evidence
Tsao C, Seng S, Oh W, Galsky M. Endocrine therapy for prostate cancer: review of the latest clinical evidence. Clinical Investigation 2011, 1: 533-541. DOI: 10.4155/cli.11.28.Peer-Reviewed Original ResearchProstate cancerEndocrine therapyAdvent of prostate-specific antigen screeningTreatment of castration-resistant prostate cancerCastration-resistant prostate cancerProstate-specific antigen screeningCombined hormone therapyComplete androgen blockadeDefinitive local therapyAndrogen blockadeCastration resistanceAndrogen deprivationAndrogen resistanceLocal therapyHormone therapyLocalized diseaseNonskin cancerAntigen screeningClinical evidenceResponse rateTherapyCancerProstateBlockadeRecurrence
2004
Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate
Tay M, Kaufman D, Regan M, Leibowitz S, George D, Febbo P, Manola J, Smith M, Kaplan I, Kantoff P, Oh W. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Annals Of Oncology 2004, 15: 974-978. PMID: 15151957, DOI: 10.1093/annonc/mdh221.Peer-Reviewed Original ResearchConceptsProstate-specific antigen nadirProstate-specific antigenSerum prostate-specific antigenAdvanced prostate cancerProstate cancerSexual functionMedian decreaseMedian time to treatment failureTime to treatment failurePrimary hormonal therapyMedian Follow-UpAndrogen blockadeAdvanced adenocarcinomaHormone therapyTreatment failureSpontaneous erectionsToxic therapiesMedian timeFollow-upDisease progressionFinasterideSide effectsBicalutamidePatientsSurgical castration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply